Description
Human Umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC), as an off-the-shelf product, was developed in South Korea and are clinically being utilized, showing promising results. Several established risk factors are associated with unfavorable outcomes following current cartilage repair procedures. Old age, cartilage defect size, malalignment, and meniscal insufficiency are the commonly mentioned risk factors. However, since hUCB-MSC implantation is indicated for large cartilage defects with degenerative changes, it is likely that most patients undergoing this treatment have multiple risk factors. The specific factors that have a significant impact on the clinical outcomes and cartilage regeneration in patients with multiple risk factors remain unclear. This study aims to analyze the prognostic factors for clinical outcomes and cartilage regeneration after the implantation of allogeneic human umbilical cord blood mesenchymal stem cell (hUCB-MSC) for treating large-sized cartilage defects with osteoarthritis.
